194473-03-5

Usage

Uses

Used in Pharmaceutical Industry:
7-FLUORO-2-METHYL-3H-QUINAZOLIN-4-ONE is used as a pharmaceutical candidate for its potential medicinal applications due to its unique structure and properties. Its quinazolinone ring and the presence of a fluorine atom and a methyl group contribute to its potential biological activity, making it a valuable compound for the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry Research:
7-FLUORO-2-METHYL-3H-QUINAZOLIN-4-ONE is used as a subject of research in medicinal chemistry to explore its potential as a lead compound for the development of new pharmaceuticals. Its unique structure and properties allow researchers to investigate its interactions with biological targets and evaluate its efficacy in treating various diseases and conditions.
Used in Drug Design and Optimization:
7-FLUORO-2-METHYL-3H-QUINAZOLIN-4-ONE is used as a starting point for drug design and optimization efforts in the pharmaceutical industry. Its quinazolinone core and substituents can be modified to improve its pharmacological properties, such as potency, selectivity, and bioavailability, leading to the development of more effective and safer drugs.
Used in Chemical Synthesis:
7-FLUORO-2-METHYL-3H-QUINAZOLIN-4-ONE is used as a building block or intermediate in the synthesis of more complex organic compounds and pharmaceuticals. Its unique structure and reactivity can be exploited in various chemical reactions to produce a wide range of derivatives with diverse applications in the fields of chemistry and medicine.

InChI:InChI=1/C9H7FN2O/c1-5-11-8-4-6(10)2-3-7(8)9(13)12-5/h2-4H,1H3,(H,11,12,13)

Upstream product

• 119023-25-5 4-fluoroanthranilamide 
• 321-50-6 7-fluoro-1H-benzo[d][1,3]oxazine-2,4-dione 
• 78-39-7 Triethyl orthoacetate 
• 446-32-2 4-fluoroanthranilic acid 
• 108-24-7 acetic anhydride 
• 128992-48-3 7-fluoro-2-methyl-4H-benzo[d][1,3]-oxazin-4-one 
• 1201935-93-4 2-amino-4-fluoro-N-methoxybenzamide 
• 75-07-0 acetaldehyde 
• 631-61-8 ammonium acetate 
• 64-19-7 acetic acid 

Downstream Products

• 1206694-32-7 4-chloro-7-fluoro-2-methyl-quinazoline 

Relevant academic research and scientific papers

One-pot synthesis of quinazolin-4(3H)-ones and 2,3-dihydroquinazolin-4(1H)-ones utilizing N-(2-aminobenzoyl)benzotriazoles

A convenient and efficient method has emerged for the one-pot synthesis of substituted quinazolin-4(3H)ones and nonaromatic alkaloids. 2-Substituted quinazolin-4(3H)-ones, 2,3-disubstituted quinazolin-4(3H)-ones, and 2,3-dihydroquinazolin-4(1H)-ones were obtained at yields of 46% to 95% by a one-pot reaction of N-(2-aminobenzoyl) benzotriazoles with amines and orthoesters or aldehydes under catalyst-free conditions.

Schizocommunin derivative and preparation method and application thereof

The invention belongs to the field of medicinal chemistry, and particularly relates to a schizocommunin derivative and a preparation method and application thereof. The structural formula of the schizocommunin derivative is shown in the description, wherein R1 and R3 are hydrogen or fluorine atoms, R2 is amidogen or substituted amidogen or a five-membered or six-membered heterocycle group, R4 is ahydrogen atom or amidogen or substituted amidogen or a five-membered or six-membered heterocycle group, R5 is a hydrogen atom or amidogen or substituted amidogen or halohydrocarbon or a five-memberedor six-membered heterocycle group, and R6 is a hydrogen atom or an alkyl group; a substituent group is amidogen or a five-membered or six-membered heterocycle group. The schizocommunin derivative hasextremely high binding and stabilizing capacities for telomere DNA which is rich in guanine, has a significant anti-cancer effect, and can be used for preparing anti-cancer drugs which have selectivity. Further experiments show that the schizocommunin derivative has significant inhibition effects on various cancer cell lines and has broad application space in anti-cancer drug preparation.

Discovery of Novel Schizocommunin Derivatives as Telomeric G-Quadruplex Ligands That Trigger Telomere Dysfunction and the Deoxyribonucleic Acid (DNA) Damage Response

Telomeric G-quadruplex targeting and telomere maintenance interference are emerging as attractive strategies for anticancer therapies. Here, a novel molecular scaffold is explored for telomeric G-quadruplex targeting. A series of novel schizocommunin derivatives was designed and synthesized as potential telomeric G-quadruplex ligands. The interaction of telomeric G-quadruplex DNA with the derivatives was explored by biophysical assay. The cytotoxicity of the derivatives toward cancer cell lines was evaluated by the methyl thiazolyl tetrazolium (MTT) assay. Among the derivatives, compound 16 showed great stabilization ability toward telomeric G-quadruplex DNA and good cytotoxicity toward cancer cell lines. Further cellular experiments indicated that 16 could induce the formation of telomeric G-quadruplex in cells, triggering a DNA damage response at the telomere and causing telomere dysfunction. These effects ultimately provoked p53-mediated cell cycle arrest and apoptosis, and suppressed tumor growth in a mouse xenograft model. Our work provides a novel scaffold for the development of telomeric G-quadruplex ligands.

Oxidant- and metal-free synthesis of 4(3H)-quinazolinones from 2-amino-N-methoxybenzamides and aldehydes via acid-promoted cyclocondensation and elimination

A series of biologically important 4(3H)-quinazolinones were readily synthesized in good to excellent yields from 2-amino-N-methoxybenzamides and aldehydes via a cascade reaction consisting of AcOH-promoted cyclocondensation and elimination. The current m

One-pot synthesis of quinazolinones from anthranilamides and aldehydes via p -toluenesulfonic acid catalyzed cyclocondensation and phenyliodine diacetate mediated oxidative dehydrogenation

A variety of 4(3H)-quinazolinones are synthesized conveniently in one pot from 2-aminobenzamides and aldehydes, via cyclization catalyzed by p-toluenesulfonic acid followed by oxidative dehydrogenation mediated by the hypervalent iodine compound phenyliodine diacetate [PhI(OAc)2, PIDA]. Highlights of the described method include the first synthesis of quinazolinones bearing an N-alkoxy substituent, a new application of phenyliodine diacetate as an efficient dehydrogenative oxidant, and mild reaction conditions. Georg Thieme Verlag Stuttgart, New York.

PHARMACEUTICAL COMPOUNDS

The invention provides a compound of the formula (I) or a salt, solvate, tautomer or N-oxide thereof for use in the treatment or prophylaxis of a disease state or condition mediated by protein kinase A and/or protein kinase B, wherein the ring Q is a benzene ring; J2-J1 is N=CR7 or R1aN-CO; G is OH or NR5R6; E is CONR7, NR7CO, C(R8)=C(R8) or (X)m(CR8R8a)n where X is O, S or NR7; provided that when J2-J1 is R1aN-CO, E is other than NR7CO; m and n are each 0 or 1, where m + n = 1 or 2; A is a bond and R4 and R4a are absent, or A is a saturated optionally substituted C1-7 hydrocarbon linker group having a maximum chain length of 5 atoms extending between E and G, one carbon atom in the linker group A being optionally replaced by O or N; R1,Rla, R2, and R3 are each H; halogen; C1-6 hydrocarbyl optionally substituted by halogen, OH or C1-2 alkoxy; CN; CONHR8; NH2; NHCOR10 or NHCONHR10; R4 is H or C1-4 alkyl; R4a is H, C1-4 alkyl or a group R9; R5 and R6 are each selected from H, R9 and C1-4 hydrocarbyl optionally substituted by halogen, C1-2 alkoxy or R9;or NR5R6 forms a saturated 4-7 membered monocyclic heterocyclic group; R7 is H or C1-4 alkyl; R8 and R8a each H or saturated C1-4 hydrocarbyl optionally substituted by fluorine; R9is a monocyclic or bicyclic carbocyclic or heterocyclic group containing up to 3 ring heteroatoms selected from N, O and S; or R4, R4a and A together form a saturated monocyclic 4-7 membered heterocycle; or NR5R6, R4 and A form a saturated 4-7 membered monocyclic heterocycle; or R4,together with R7 or R8 and A and E form a 4-7 membered saturated monocyclic heterocycle; or NR5R6 and R7 or R8 together with A and E form a 4-7 membered saturated monocyclic heterocycle; and R10 is optionally substituted phenyl or benzyl.